Regulus Therapeutics (RGLS) News Today

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy r

CVI Holdings LLC bought a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,406,250 shares of the biopharmaceutical company's stock, valued at ap

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 5,300,000 shares, an increase of 48.0% from the June 15th total of 3,580,000 shares. Based on an average trading volume of 798,700 shares, the days-to-cover ratio is presently 6.6 days. Approximately 10.0% of the shares of the company are short sold.

Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Regulus Therapeutics in a research note issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will pos

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have giv

Canaccord Genuity Group boosted their price target on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a "buy" rating in a research report on Tuesday.

Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above 200-Day Moving Average of $1.87

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 4,210,000 shares, a decline of 32.9% from the April 15th total of 6,270,000 shares. Based on an average daily volume of 3,040,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 7.3% of the shares of the company are short sold.

HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday.

Vivo Capital LLC bought a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,000,000 shares of the biopharmaceutical company's

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,130,000 shares, a growth of 9,244.3% from the February 29th total of 54,900 shares. Currently, 13.0% of the shares of the company are sold short. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is currently 1.8 days.

HC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday.